The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
ginsenoside Rg3 results in increased degradation of AR protein ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of AR protein]
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]
ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein] 3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]
ginsenoside Rg3 results in increased cleavage of CASP3 protein [ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of CASP3 protein; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP3 protein]
EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]
EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]; ginsenoside Rg3 results in decreased expression of and affects the localization of EGFR protein
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of FUT4 protein] ginsenoside Rg3 results in decreased expression of FUT4 protein
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of HSF1 protein] ginsenoside Rg3 results in decreased expression of HSF1 protein
ginsenoside Rg3 results in increased expression of IL1B protein ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of IL1B protein]
ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of KLK3 mRNA]; ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of KLK3 protein]
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein ginsenoside Rg3 results in increased activity of NFKB1 protein
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein; [ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein
ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein] 3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]
NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]]
Staurosporine inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein] ginsenoside Rg3 results in increased expression of NOS2 mRNA
[staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of NTRK2 protein modified form]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3]
ginsenoside Rg3 results in increased cleavage of PARP1 protein [ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of PARP1 protein; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of PARP1 protein]
ginsenoside Rg3 results in decreased expression of PROM1 mRNA XMU-MP-1 inhibits the reaction [ginsenoside Rg3 results in decreased expression of PROM1 mRNA]
ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein] 3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein; ginsenoside Rg3 affects the localization of and results in increased activity of RELA protein ginsenoside Rg3 results in decreased expression of and results in decreased phosphorylation of RELA protein
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A2 protein]
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A3 protein]
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]
ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein] 3-methyladenine affects the reaction [ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein]]; ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein]
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]
ginsenoside Rg3 results in increased expression of TNF protein ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; ginsenoside Rg3 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]]
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]]
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA]
ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG mRNA]; ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG protein]
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA] ginsenoside Rh1 results in decreased expression of TNF ginsenoside Rh1 results in decreased susceptibility to TNF protein
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA]]; Escin inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA]] Escin results in increased expression of ACACA mRNA Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of ACACA mRNA]
Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ACOX1 mRNA] ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA]]; Escin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA]]
Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG5 protein] Escin results in increased expression of ATG5 protein ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT2 mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SQSTM1 protein]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 protein]]; ATG5 protein affects the reaction [Escin promotes the reaction [Dietary Fats results in increased lipidation of MAP1LC3B protein]]; Escin inhibits the reaction [Dietary Fats results in decreased expression of ATG5 protein]; Escin inhibits the reaction [tyloxapol results in decreased expression of ATG5 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ATG5 protein]]
Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG7 protein] Escin inhibits the reaction [Dietary Fats results in decreased expression of ATG7 protein]; Escin inhibits the reaction [tyloxapol results in decreased expression of ATG7 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ATG7 protein]]
Escin results in increased expression of BECN1 protein Escin inhibits the reaction [Dietary Fats results in decreased expression of BECN1 protein]; Escin inhibits the reaction [tyloxapol results in decreased expression of BECN1 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of BECN1 protein]]
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]]; Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]] Escin results in increased expression of CPT1A mRNA
Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA] ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT2 mRNA]]; Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT2 mRNA]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT2 mRNA]]
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]]; Escin inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]] Escin results in decreased expression of FAS mRNA
Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLC protein] Escin results in increased expression of GCLC protein Escin inhibits the reaction [Dietary Fats results in decreased expression of GCLC protein]; Escin inhibits the reaction [tyloxapol results in decreased expression of GCLC protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of GCLC protein]]
Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLM protein] Escin inhibits the reaction [Dietary Fats results in decreased expression of GCLM protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of GCLM protein]] Escin results in increased expression of GCLM protein
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]]; Escin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]; Escin inhibits the reaction [tyloxapol results in increased expression of GPT protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]]
Escin inhibits the reaction [Dietary Fats results in decreased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of HMOX1 protein]] Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein] Escin results in increased expression of HMOX1 protein
Escin inhibits the reaction [Dietary Fats results in increased expression of KEAP1 protein]; Escin inhibits the reaction [tyloxapol results in increased expression of KEAP1 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of KEAP1 protein]] Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of KEAP1 protein] Escin results in increased expression of KEAP1 protein
Escin results in increased lipidation of MAP1LC3B protein ATG5 protein affects the reaction [Escin promotes the reaction [Dietary Fats results in increased lipidation of MAP1LC3B protein]]; Escin inhibits the reaction [tyloxapol results in increased lipidation of MAP1LC3B protein]; Escin promotes the reaction [Dietary Fats results in increased lipidation of MAP1LC3B protein]; NFE2L2 protein affects the reaction [Escin promotes the reaction [Dietary Fats results in increased lipidation of MAP1LC3B protein]]
[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein; [Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein]; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein]; Y 27632 inhibits the reaction [[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein]; Y 27632 inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein]
Escin results in increased expression of NFE2L2 protein Escin inhibits the reaction [Dietary Fats results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ATG5 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ATG7 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of BECN1 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT2 mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of GCLC protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of GCLM protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of HMOX1 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of NQO1 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of KEAP1 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SQSTM1 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 protein]]; NFE2L2 protein affects the reaction [Escin promotes the reaction [Dietary Fats results in increased lipidation of MAP1LC3B protein]] Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NFE2L2 protein]; Escin results in increased expression of and affects the localization of NFE2L2 protein
Escin inhibits the reaction [Dietary Fats results in decreased expression of NQO1 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of NQO1 protein]] Escin results in increased expression of NQO1 protein Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NQO1 protein]
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein]]; Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA]; Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein]; Escin inhibits the reaction [tyloxapol results in decreased expression of PPARA protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein]]
Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PPARG protein] Escin results in increased expression of PPARG protein
[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein]
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SQSTM1 protein]]; Escin inhibits the reaction [Dietary Fats results in increased expression of SQSTM1 protein]; Escin inhibits the reaction [tyloxapol results in increased expression of SQSTM1 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SQSTM1 protein]] Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SQSTM1 protein]
Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 mRNA]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 protein] ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 protein]]; Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]; Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 protein]; Escin inhibits the reaction [tyloxapol results in increased expression of SREBF1 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 protein]] Escin results in increased expression of SREBF1 mRNA; Escin results in increased expression of SREBF1 protein
3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in decreased expression of BECN1 protein]]; anemoside B4 inhibits the reaction [Lipopolysaccharides results in decreased expression of BECN1 protein]
3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in decreased activity of CAT protein]]; anemoside B4 inhibits the reaction [Lipopolysaccharides results in decreased activity of CAT protein]
3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; anemoside B4 inhibits the reaction [Cisplatin results in increased expression of IL1B protein]; anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]
3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of SQSTM1 protein]]; anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of SQSTM1 protein]
anemoside B4 results in decreased secretion of TNF protein 3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; anemoside B4 inhibits the reaction [Cisplatin results in increased expression of TNF protein]; anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
asiaticoside results in increased expression of NGF protein asiaticoside inhibits the reaction [Rotenone results in decreased expression of NGF protein]
asiaticoside inhibits the reaction [Rotenone results in decreased expression of PDPK1 mRNA]; asiaticoside inhibits the reaction [Rotenone results in decreased expression of PDPK1 protein]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of AKT1 mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of AKT1 protein
astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of ATP2A2 protein]; astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of ATP2A2 mRNA]
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CASP3 protein modified form] astragaloside A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein]
astragaloside IV decreases expression Dusp5 mRNA and protein in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate increases expression of DUSP5 mRNA and protein in Vascular smooth muscle cells]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of EGFR mRNA
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein]
astragaloside IV increases expression H19 RNA in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases expression of H19 RNA in Vascular smooth muscle cells]
astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of HDAC9 protein]
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein astragaloside A results in increased expression of HMOX1 mRNA; astragaloside A results in increased expression of HMOX1 protein
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL1B protein; astragaloside A inhibits the reaction [Cisplatin results in increased expression of IL1B protein]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL6 protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein] astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]
astragaloside IV decreases expression of Khdrbs1 protein in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate astragaloside IV increases expression of KHDRBS1 protein in Vascular smooth muscle cells]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of MMP9 protein
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of MTOR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MTOR mRNA astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases phoshorylation of MTOR protein in Vascular smooth muscle cells] astragaloside IV increases phosphorylation Mtor protein in thoracic aorta
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5AC mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of MUC5AC protein
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5B mRNA
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein astragaloside A affects the localization of NFE2L2 protein
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein]
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein]
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein]
astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA]
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of TIMP1 protein
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of TNF protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein] astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]
bacoside A inhibits the reaction [Tobacco Smoke Pollution results in decreased activity of CAT protein] bacoside A results in increased activity of CAT protein
bacoside A results in increased activity of GSR protein bacoside A inhibits the reaction [Tobacco Smoke Pollution results in decreased activity of GSR protein]
[ginsenoside M1 co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; ginsenoside M1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of CXCR1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] ginsenoside M1 results in decreased expression of TNF mRNA ginsenoside M1 results in decreased susceptibility to TNF protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of BMP2 mRNA] ginsenoside Rb1 results in increased expression of BMP2 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; ginsenoside Rb1 results in increased expression of and results in increased activity of HMOX1 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein] [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of IGF1 mRNA] ginsenoside Rb1 results in increased expression of IGF1 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; [ginsenoside Rb1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; ginsenoside Rb1 results in increased activity of and results in increased localization of NFE2L2 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein] ginsenoside Rb1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein ginsenoside Rb1 results in increased expression of NFE2L2 mRNA
ginsenoside Rb1 results in increased expression of RUNX2 mRNA ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of RUNX2 mRNA]
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein] ginsenoside Rb1 results in decreased expression of SQSTM1 protein
[ginsenoside Rb1 co-treated with alpha-Chlorohydrin] affects the localization of TFEB protein; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of TFEB mRNA]
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of TGFB1 mRNA] ginsenoside Rb1 results in increased expression of TGFB1 mRNA
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] ginsenoside Rb1 results in decreased susceptibility to TNFSF11 protein
ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA]
ginsenoside Rd results in increased expression of CDKN1A mRNA staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CDKN1A mRNA]
ginsenoside Rd results in increased expression of CHAT mRNA; ginsenoside Rd results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT protein]
ginsenoside Re results in increased expression of ADIPOQ mRNA ginsenoside Re results in increased expression of and results in increased secretion of ADIPOQ protein
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of AIF1 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of AIF1 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]] ginsenoside Re results in decreased expression of AIF1 protein
ginsenoside Re results in increased phosphorylation of and results in increased activity of AKT1 protein ginsenoside Re results in increased phosphorylation of AKT1 protein
ginsenoside Re results in decreased expression of BAX mRNA; ginsenoside Re results in decreased expression of BAX protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; Acetylcysteine inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]]; Cyclosporine inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]
ginsenoside Re results in increased expression of BCL2 mRNA; ginsenoside Re results in increased expression of BCL2 protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein]
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re results in decreased cleavage of and results in decreased activity of CASP3 protein; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]
ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]]
ginsenoside Re results in increased expression of CHAT mRNA; ginsenoside Re results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT protein]
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [Phencyclidine results in increased activity of CYBA protein]
ginsenoside Re results in decreased expression of FAS mRNA ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]
ginsenoside Re affects the reaction [GPX1 protein affects the expression of AIF1 protein]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of and affects the localization of RELA protein]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of PTAFR protein]; ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK1 protein]; ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK3 protein]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]]
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA]
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK1 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRAK1 protein]
ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein] ginsenoside Re results in increased expression of IRS1 mRNA ginsenoside Re results in increased phosphorylation of IRS1 protein
ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK1 protein]; ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK1 protein ginsenoside Re results in increased phosphorylation of MAPK1 protein
ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK3 protein]; ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK3 protein ginsenoside Re results in increased phosphorylation of MAPK3 protein
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [Phencyclidine affects the localization of NCF1 protein]
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] ginsenoside Re results in decreased expression of NOS2 protein
2-aminoethoxydiphenyl borate inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Calcium deficiency inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Mifepristone inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of PCK1 mRNA] ginsenoside Re results in decreased expression of PCK1 mRNA
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of PDYN mRNA]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]
ginsenoside Re results in increased phosphorylation of PRKAA1 protein ginsenoside Re inhibits the reaction [Dietary Fats results in decreased phosphorylation of PRKAA1 protein]
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of and results in increased cleavage of PRKCD protein] PRKCD results in increased susceptibility to ginsenoside Re
ginsenoside Re affects the reaction [GPX1 protein affects the expression of PTAFR protein] ginsenoside Re results in decreased expression of PTAFR protein
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]
ginsenoside Re affects the reaction [GPX1 protein affects the expression of and affects the localization of RELA protein]; ginsenoside Re results in decreased expression of and affects the localization of RELA protein
ginsenoside Re results in decreased expression of SCD mRNA ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SCD1 mRNA]
ginsenoside Re inhibits the reaction [Dietary Fats inhibits the reaction [INS1 protein results in increased localization of SLC2A4 protein]] ginsenoside Re results in increased localization of SLC2A4 protein
SLCO1B2 protein binds to and results in increased transport of ginsenoside Re SLCO1B3 protein binds to and results in increased transport of ginsenoside Re
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] ginsenoside Re results in decreased activity of SOD1 protein
ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased activity of SOD2 protein]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]]
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] ginsenoside Re results in decreased expression of SREBF1 mRNA
ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]]
ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of and results in decreased activity of TH protein] 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of TH protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA]; ginsenoside Re results in decreased expression of and results in decreased secretion of TNF protein
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]] ginsenoside Rf results in decreased expression of APOA1 protein
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of APOC3 protein
ginsenoside Rf binds to and results in decreased activity of PPARA protein; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased activity of PPARA protein]; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased expression of PPARA mRNA]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of PPARA mRNA
ABCB11 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCB11 protein]
ABCC2 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]] ginsenoside Rg1 results in increased expression of ABCC2 protein
ginsenoside Rg1 results in increased expression of ABCC3 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]]
ginsenoside Rg1 results in increased expression of ABCC4 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC4 protein]
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of AKT1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased phosphorylation of AKT1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein] ginsenoside Rg1 inhibits the reaction [Doxorubicin results in increased expression of AKT1 mRNA]
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein alternative form]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]; ginsenoside Rg1 results in decreased susceptibility to [APP protein alternative form co-treated with Dexamethasone]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]; Mifepristone inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; SH-6 compound inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]
ginsenoside Rg1 results in increased expression of BAX protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of BAX protein] ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of BAX mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]
ginsenoside Rg1 results in decreased expression of BCL2 protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 protein]
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP3 mRNA] ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP3 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein] ginsenoside Rg1 results in increased activity of CASP3 protein
ginsenoside Rg1 results in increased activity of CASP9 protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP9 protein] ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP9 mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of CAT protein]
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein]
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDKN1A protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 protein]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 protein]
ginsenoside Rg1 results in increased expression of GCLC mRNA ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]
ginsenoside Rg1 results in increased expression of GCLM protein ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM protein]
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein]
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]] ginsenoside Rg1 results in increased expression of HMOX1 mRNA; ginsenoside Rg1 results in increased expression of HMOX1 protein
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein]
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of IL6 protein] ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
Mifepristone inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 mRNA]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 protein]
ginsenoside Rg1 results in decreased expression of MIR23A mRNA Mifepristone inhibits the reaction [ginsenoside Rg1 results in decreased expression of MIR23A mRNA]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein] ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of MTOR protein]
[ginsenoside Rg1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein ginsenoside Rg1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]] ginsenoside Rg1 results in increased expression of NFE2L2 mRNA
ginsenoside Rg1 affects the phosphorylation of NFKBIA protein PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein]
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 protein]
SLCO1B2 protein binds to and results in increased transport of ginsenoside Rg1 SLCO1B3 protein binds to and results in increased transport of ginsenoside Rg1
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein]
ginsenoside Rg2 results in decreased expression of G6PC3 mRNA dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of G6PC3 mRNA]
ginsenoside Rg2 results in increased phosphorylation of GSK3B protein [[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of GSK3B protein]
[[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; [ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein
ginsenoside Rg2 results in increased phosphorylation of STK11 protein dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of STK11 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased phosphorylation of AKT1 protein]
ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of GCK mRNA]; ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of GCK protein] ginsenoside Rh4 inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of GCK mRNA]
ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of GCLC mRNA]; ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of GCLC protein]; NFE2L2 protein affects the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of GCLC protein]] ginsenoside Rh4 inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of GCLC mRNA]
ginsenoside Rh4 inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of HMOX1 mRNA] ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of HMOX1 mRNA]; ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of HMOX1 protein]]
ginsenoside Rh4 inhibits the reaction [Alloxan inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; NFE2L2 protein affects the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan inhibits the reaction [Glucose results in increased secretion of INS1 protein]]] ginsenoside Rh4 inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of INS1 mRNA]; ginsenoside Rh4 inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of INS1 protein]
ginsenoside Rh4 inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of NFE2L2 mRNA]; ginsenoside Rh4 inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of NFE2L2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan affects the localization of NFE2L2 protein]]; ginsenoside Rh4 inhibits the reaction [Alloxan affects the localization of NFE2L2 protein]; ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of NFE2L2 mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan inhibits the reaction [Glucose results in increased secretion of INS1 protein]]]; NFE2L2 protein affects the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of GCLC protein]]; NFE2L2 protein affects the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of HMOX1 protein]]; NFE2L2 protein affects the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of NQO1 protein]]
ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of NQO1 mRNA]; ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of NQO1 protein]; NFE2L2 protein affects the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of NQO1 protein]]
ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of PDX1 mRNA]; ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of PDX1 protein] ginsenoside Rh4 inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of PDX1 mRNA]; ginsenoside Rh4 inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of PDX1 protein]
ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of SLC2A2 mRNA]; ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased expression of SLC2A2 protein] ginsenoside Rh4 inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of SLC2A2 mRNA]
Glycyrrhizic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Glycyrrhizic Acid results in decreased activity of ABCB11 protein
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP3 protein]; Glycyrrhizic Acid inhibits the reaction [Fusaric Acid results in decreased expression of CASP3 protein] Glycyrrhizic Acid results in increased activity of CASP3 protein
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP8 protein] Glycyrrhizic Acid results in increased activity of CASP8 protein
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP9 protein] Glycyrrhizic Acid results in increased activity of CASP9 protein
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPB mRNA]
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPD mRNA]
NR1I2 protein affects the reaction [Glycyrrhizic Acid results in increased expression of CYP3A4 mRNA] Glycyrrhizic Acid results in increased expression of CYP3A4 mRNA; Glycyrrhizic Acid results in increased expression of CYP3A4 protein
Glycyrrhizic Acid results in decreased expression of CYP7A1 mRNA Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA]
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]
Glycyrrhizic Acid inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with BCG Vaccine] results in increased activity of GPT protein] Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]
Glycyrrhizic Acid results in decreased secretion of HMGB1 protein Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of HMGB1 protein] Glycyrrhizic Acid results in decreased activity of HMGB1 protein
Glycyrrhizic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 mRNA]; Glycyrrhizic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of [IL12A protein binds to IL12B protein]; [Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of IL12A mRNA
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of [IL12A protein binds to IL12B protein]; [Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of IL12B mRNA; [Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of IL12B protein
Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein] Glycyrrhizic Acid inhibits the reaction [Histamine results in increased expression of IL6 mRNA]; Glycyrrhizic Acid inhibits the reaction [Histamine results in increased secretion of IL6 protein] Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of IL6 mRNA]; Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of IL6 protein]
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPB mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPD mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of LPL mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SCD1 mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SLC2A4 mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of MAPK1 protein]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of MAPK3 protein]
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of LPL mRNA]
[Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased lipidation of MAP1LC3B protein]
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of MAPK1 protein]
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of MAPK3 protein]
Glycyrrhizic Acid inhibits the reaction [Histamine results in increased expression of MUC5AC mRNA]; Glycyrrhizic Acid inhibits the reaction [Histamine results in increased secretion of MUC5AC protein]
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]
Glycyrrhizic Acid results in increased activity of NR1I2 protein NR1I2 protein affects the reaction [Glycyrrhizic Acid results in increased expression of CYP3A4 mRNA]
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased activity of [NFKB1 protein binds to RELA protein] Glycyrrhizic Acid inhibits the reaction [Histamine results in increased phosphorylation of RELA protein] Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene affects the localization of RELA protein]; Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased phosphorylation of RELA protein]
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SCD1 mRNA]
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SLC2A4 mRNA]
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of TJP1 protein]; Glycyrrhizic Acid inhibits the reaction [Palmitic Acid results in decreased expression of TJP1 protein]
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of TJP2 protein]; Glycyrrhizic Acid inhibits the reaction [Palmitic Acid results in decreased expression of TJP2 protein]
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein] Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of TNF mRNA]; Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein]
gypenoside LXXV results in increased phosphorylation of AKT1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased phosphorylation of AKT1 protein]
gypenoside LXXV results in increased expression of and results in increased secretion of CTGF protein gypenoside LXXV results in increased expression of CTGF mRNA
gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL1B protein]
gypenoside LXXV results in decreased phosphorylation of IRS1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in decreased expression of and results in decreased phosphorylation of IRS1 protein]; gypenoside LXXV results in decreased expression of and results in decreased phosphorylation of IRS1 protein
gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of CCL2 protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL1B protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL6 protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of TNF protein]
gypenoside LXXV results in increased expression of PPARG protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased expression of PPARG protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV binds to and results in increased activity of PPARG protein]; gypenoside LXXV binds to and results in increased activity of PPARG protein
gypenoside LXXV affects the localization of SLC2A4 protein gypenoside LXXV results in increased expression of SLC2A4 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gypenoside LXXV affects the localization of SLC2A4 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV affects the localization of SLC2A4 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased expression of SLC2A4 protein]
gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of TNF protein]; gypenoside LXXV inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
madecassoside inhibits the reaction [Cisplatin results in increased expression of BAX mRNA] madecassoside inhibits the reaction [Cisplatin results in increased expression of BAX mRNA]; madecassoside inhibits the reaction [Cisplatin results in increased expression of BAX protein]
madecassoside inhibits the reaction [Cisplatin results in increased expression of LCN2 mRNA]; madecassoside inhibits the reaction [Cisplatin results in increased expression of LCN2 protein]
notoginsenoside R1 results in increased expression of ABCB1 mRNA notoginsenoside R1 results in increased expression of ABCB1A mRNA NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA]
notoginsenoside R1 results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of AKT1 protein]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein]
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased abundance of Glutathione]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased expression of MIR20A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Triglycerides]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR126A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR21A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein]
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form] notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK8 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK9 protein]
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; Cyclosporine inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein] notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]
notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] notoginsenoside R1 results in increased expression of BCL2 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; Cyclosporine inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein modified form]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein] 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]
notoginsenoside R1 results in increased phosphorylation of and results in increased activity of ESR1 protein notoginsenoside R1 results in increased expression of ESR1; notoginsenoside R1 results in increased expression of ESR1 mRNA; notoginsenoside R1 results in increased expression of ESR1 protein [1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole results in decreased activity of ESR1 protein] which results in decreased susceptibility to notoginsenoside R1; [notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein; fulvestrant inhibits the reaction [[notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein]
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA]
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of GCLC protein]
fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]] notoginsenoside R1 results in increased expression of GSK3B protein modified form
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein notoginsenoside R1 results in increased expression of HMOX1; notoginsenoside R1 results in increased expression of HMOX1 protein Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of HMOX1 protein]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; Fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL2 mRNA]
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; Fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 protein]
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 protein]
notoginsenoside R1 results in decreased expression of ITGB2 protein notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein]
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK1 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein]
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK3 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein] notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] notoginsenoside R1 results in decreased expression of MPO protein
notoginsenoside R1 affects the localization of NFE2L2 protein NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide affects the localization of NFE2L2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased expression of and affects the localization of NFE2L2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased expression of and affects the localization of NFE2L2 protein]; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased expression of and affects the localization of NFE2L2 protein]; notoginsenoside R1 results in increased expression of and affects the localization of NFE2L2 protein
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; notoginsenoside R1 promotes the reaction [Lipopolysaccharides results in increased expression of NFKBIA mRNA] fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] [notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of NQO1 protein]
notoginsenoside R1 binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of UGT1A1 mRNA] notoginsenoside R1 results in increased activity of NR1I2 protein NR1I2 protein results in increased susceptibility to notoginsenoside R1
notoginsenoside R1 results in increased expression of PLAT mRNA; notoginsenoside R1 results in increased expression of PLAT protein notoginsenoside R1 results in increased expression of [PLAT protein binds to SERPINE1 protein]
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein]
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein modified form]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein modified form] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of RELA protein]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of RELA protein]
notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of ROCK1 protein]
notoginsenoside R1 results in increased expression of RUNX2 mRNA fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of RUNX2 mRNA]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 results in increased expression of [PLAT protein binds to SERPINE1 protein] notoginsenoside R1 results in decreased activity of SERPINE1 protein
SLCO1B2 protein binds to and results in increased transport of notoginsenoside R1 SLCO1B3 protein binds to and results in increased transport of notoginsenoside R1
notoginsenoside R1 affects the localization of SQSTM1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 affects the localization of SQSTM1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate affects the localization of SQSTM1 protein]]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate affects the localization of SQSTM1 protein]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] notoginsenoside R1 results in decreased expression of TNF 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TRP53 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TRP53 protein]
notoginsenoside R1 results in increased expression of UGT1A1 mRNA NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of UGT1A1 mRNA]
platycodin D affects the expression of AKT1 protein modified form platycodin D results in increased phosphorylation of AKT1 protein [platycodin D co-treated with Imatinib Mesylate] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; [platycodin D results in decreased activity of AKT1 protein] which results in decreased phosphorylation of and results in decreased localization of TERT protein platycodin D results in decreased phosphorylation of AKT1 protein platycodin D results in decreased expression of AKT1 protein modified form platycodin D inhibits the reaction [TNFSF11 protein results in increased phosphorylation of and results in increased activity of AKT1 protein]
Everolimus promotes the reaction [platycodin D results in decreased expression of BIRC5 protein]; platycodin D promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]
[MK 2206 co-treated with platycodin D] results in increased activity of CASP3 protein; [platycodin D co-treated with Imatinib Mesylate] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [platycodin D results in increased activity of CASP3 protein] platycodin D results in increased cleavage of CASP3 protein
[platycodin D co-treated with Imatinib Mesylate] results in increased cleavage of CASP9 protein platycodin D results in increased cleavage of CASP9 protein platycodin D results in increased activity of CASP9 protein
Chlorpromazine inhibits the reaction [platycodin D results in decreased expression of and results in increased secretion of CD274 protein]; platycodin D results in decreased expression of and results in increased secretion of CD274 protein platycodin D results in increased expression of CD274 mRNA
platycodin D results in decreased expression of CEBPA mRNA; platycodin D results in decreased expression of CEBPA protein CTNNB1 affects the reaction [platycodin D results in decreased expression of CEBPA protein]
CTNNB1 affects the reaction [platycodin D results in decreased expression of CEBPA protein]; CTNNB1 affects the reaction [platycodin D results in decreased expression of FABP4 protein]; CTNNB1 affects the reaction [platycodin D results in increased expression of CCND1 mRNA]; CTNNB1 affects the reaction [platycodin D results in increased expression of PPARG mRNA]; platycodin D results in increased expression of and results in increased localization of CTNNB1 protein
platycodin D results in decreased expression of EGFR protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [platycodin D results in decreased expression of EGFR protein]; platycodin D inhibits the reaction [Everolimus results in increased expression of EGFR protein]; platycodin D inhibits the reaction [MK 2206 results in increased expression of EGFR protein]
platycodin D results in increased expression of EGR1 mRNA Acetylcysteine inhibits the reaction [platycodin D results in increased expression of EGR1 mRNA]
[platycodin D co-treated with MK 2206] results in decreased phosphorylation of EIF4EBP1 protein; Everolimus promotes the reaction [platycodin D results in decreased phosphorylation of EIF4EBP1 protein]; platycodin D promotes the reaction [Everolimus results in decreased phosphorylation of EIF4EBP1 protein] platycodin D results in decreased expression of EIF4EBP1 protein modified form
platycodin D results in decreased expression of ERBB2 protein platycodin D inhibits the reaction [MK 2206 results in increased expression of ERBB2 protein]
CTNNB1 affects the reaction [platycodin D results in decreased expression of FABP4 protein] platycodin D results in decreased expression of FABP4 mRNA; platycodin D results in decreased expression of FABP4 protein
dorsomorphin inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of FAS mRNA]]; dorsomorphin inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of FAS protein]]; platycodin D inhibits the reaction [Glucose results in increased expression of FAS mRNA]; platycodin D inhibits the reaction [Glucose results in increased expression of FAS protein]; STO 609 inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of FAS mRNA]] platycodin D results in increased expression of FAS protein
platycodin D results in increased expression of FOXO3 protein MDM2 protein inhibits the reaction [platycodin D results in increased expression of FOXO3 protein] platycodin D results in decreased expression of FOXO3 protein modified form
platycodin D inhibits the reaction [Alloxan results in decreased expression of FOXP3 protein]; platycodin D inhibits the reaction [TGFB1 protein results in decreased expression of FOXP3 protein]
platycodin D inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CCL17 mRNA]; platycodin D inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; platycodin D inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; platycodin D inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of STAT1 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [platycodin D results in decreased expression of IGF1R protein]; platycodin D inhibits the reaction [Everolimus results in increased expression of IGF1R protein]
platycodin D inhibits the reaction [Alloxan results in decreased expression of and results in decreased secretion of IL10 protein]; platycodin D inhibits the reaction [TGFB1 protein results in decreased expression of and results in decreased secretion of IL10 protein]
platycodin D inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of and results in increased secretion of IL17A protein]; platycodin D inhibits the reaction [Alloxan results in increased expression of and results in increased secretion of IL17A protein]
platycodin D inhibits the reaction [[[S100A8 protein binds to S100A9 protein] which results in increased localization of and results in increased activity of RELA protein] which results in increased expression of IL1B protein]; platycodin D inhibits the reaction [Alloxan results in increased expression of and results in increased secretion of IL1B protein]; platycodin D inhibits the reaction [Ethanol results in increased expression of and results in increased secretion of IL1B protein] platycodin D inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein]; platycodin D inhibits the reaction [IL1B protein results in increased expression of NR1H3 protein]; platycodin D inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]; platycodin D inhibits the reaction [IL1B protein results in increased secretion of CCL5 protein]; platycodin D inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]; platycodin D inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein]; platycodin D inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] platycodin D inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]
platycodin D inhibits the reaction [[[S100A8 protein binds to S100A9 protein] which results in increased localization of and results in increased activity of RELA protein] which results in increased expression of IL6 protein]; platycodin D inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of and results in increased secretion of IL17A protein]; platycodin D inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC protein]; platycodin D inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased phosphorylation of STAT3 protein]; platycodin D inhibits the reaction [Alloxan results in increased expression of and results in increased secretion of IL6 protein]; platycodin D inhibits the reaction [Ethanol results in increased expression of and results in increased secretion of IL6 protein] platycodin D inhibits the reaction [Ethanol results in increased expression of IL6 protein]; platycodin D inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
platycodin D results in increased expression of KLF2 mRNA KLF2 affects the reaction [platycodin D results in decreased activity of PPARG protein]; KLF2 affects the reaction [platycodin D results in decreased expression of PPARG mRNA]
Acetylcysteine inhibits the reaction [platycodin D affects the phosphorylation of and results in increased activity of MAP3K5 protein]; platycodin D affects the phosphorylation of and results in increased activity of MAP3K5 protein
platycodin D results in decreased phosphorylation of MAPK1 protein U 0126 inhibits the reaction [platycodin D results in increased phosphorylation of MAPK1 protein] platycodin D inhibits the reaction [TNFSF11 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] platycodin D results in increased activity of MAPK1 protein
platycodin D results in increased activity of MAPK3 protein platycodin D inhibits the reaction [TNFSF11 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] U 0126 inhibits the reaction [platycodin D results in increased phosphorylation of MAPK3 protein] platycodin D results in decreased phosphorylation of MAPK3 protein
platycodin D results in decreased expression of MDM2 protein MDM2 protein inhibits the reaction [platycodin D results in increased expression of FOXO3 protein]
platycodin D results in decreased activity of MMP9 protein platycodin D results in decreased expression of MMP9 protein platycodin D results in decreased expression of MMP9 mRNA
platycodin D results in decreased phosphorylation of MTOR protein [platycodin D co-treated with Imatinib Mesylate] results in decreased phosphorylation of and results in decreased expression of MTOR protein
platycodin D affects the expression of and affects the localization of NFATC1 protein platycodin D inhibits the reaction [TNFSF11 protein results in increased expression of and results in increased activity of NFATC1 protein]
platycodin D results in increased activity of [NFKB1 protein binds to RELA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [platycodin D results in increased activity of [NFKB1 protein binds to RELA protein]]
platycodin D inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; platycodin D inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein] platycodin D results in increased degradation of NFKBIA protein
platycodin D results in decreased expression of NOS2 protein platycodin D inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; platycodin D inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
platycodin D results in increased cleavage of PARP1 protein platycodin D results in increased activity of PARP1 protein [platycodin D co-treated with Imatinib Mesylate] results in increased cleavage of and results in decreased expression of PARP1 protein
platycodin D results in decreased expression of PPARG protein platycodin D results in decreased activity of PPARG protein CTNNB1 affects the reaction [platycodin D results in increased expression of PPARG mRNA]; KLF2 affects the reaction [platycodin D results in decreased activity of PPARG protein]; KLF2 affects the reaction [platycodin D results in decreased expression of PPARG mRNA] platycodin D results in decreased expression of PPARG mRNA; platycodin D results in decreased expression of PPARG protein
platycodin D results in increased phosphorylation of and results in increased activity of PRKAA1 protein platycodin D results in increased phosphorylation of PRKAA1 protein
platycodin D inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] platycodin D inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; platycodin D inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
platycodin D results in decreased activity of RELA protein platycodin D inhibits the reaction [Ethanol results in increased expression of RELA protein modified form]; platycodin D inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] platycodin D results in increased localization of RELA protein platycodin D inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; platycodin D inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]; platycodin D results in increased activity of [NFKB1 protein binds to RELA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [platycodin D results in increased activity of [NFKB1 protein binds to RELA protein]] platycodin D inhibits the reaction [[[S100A8 protein binds to S100A9 protein] which results in increased localization of and results in increased activity of RELA protein] which results in increased expression of IL1B protein]; platycodin D inhibits the reaction [[[S100A8 protein binds to S100A9 protein] which results in increased localization of and results in increased activity of RELA protein] which results in increased expression of IL6 protein]; platycodin D inhibits the reaction [[[S100A8 protein binds to S100A9 protein] which results in increased localization of and results in increased activity of RELA protein] which results in increased expression of TNF protein]; platycodin D inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein]
platycodin D inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC protein]; platycodin D inhibits the reaction [Alloxan results in increased expression of RORC protein]
platycodin D inhibits the reaction [[[S100A8 protein binds to S100A9 protein] which results in increased localization of and results in increased activity of RELA protein] which results in increased expression of IL1B protein]; platycodin D inhibits the reaction [[[S100A8 protein binds to S100A9 protein] which results in increased localization of and results in increased activity of RELA protein] which results in increased expression of IL6 protein]; platycodin D inhibits the reaction [[[S100A8 protein binds to S100A9 protein] which results in increased localization of and results in increased activity of RELA protein] which results in increased expression of TNF protein]
platycodin D inhibits the reaction [[[S100A8 protein binds to S100A9 protein] which results in increased localization of and results in increased activity of RELA protein] which results in increased expression of IL1B protein]; platycodin D inhibits the reaction [[[S100A8 protein binds to S100A9 protein] which results in increased localization of and results in increased activity of RELA protein] which results in increased expression of IL6 protein]; platycodin D inhibits the reaction [[[S100A8 protein binds to S100A9 protein] which results in increased localization of and results in increased activity of RELA protein] which results in increased expression of TNF protein]
[platycodin D co-treated with osthol] inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; [platycodin D co-treated with osthol] results in decreased expression of SMAD2 mRNA; [platycodin D co-treated with osthol] results in decreased expression of SMAD2 protein
[platycodin D co-treated with osthol] inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]; [platycodin D co-treated with osthol] results in decreased expression of SMAD3 mRNA; [platycodin D co-treated with osthol] results in decreased expression of SMAD3 protein
[platycodin D co-treated with osthol] results in decreased expression of SMAD4 mRNA; [platycodin D co-treated with osthol] results in decreased expression of SMAD4 protein
dorsomorphin inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 mRNA]]; dorsomorphin inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]]; Niacinamide inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]]; platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 mRNA]; platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]; STO 609 inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 mRNA]]
platycodin D results in decreased expression of TERT mRNA [platycodin D results in decreased activity of AKT1 protein] which results in decreased phosphorylation of and results in decreased localization of TERT protein
[platycodin D co-treated with osthol] inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; [platycodin D co-treated with osthol] inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] platycodin D inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of and results in increased secretion of IL17A protein]; platycodin D inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC protein]; platycodin D inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased phosphorylation of STAT3 protein]; platycodin D inhibits the reaction [TGFB1 protein results in decreased expression of and results in decreased secretion of IL10 protein]; platycodin D inhibits the reaction [TGFB1 protein results in decreased expression of FOXP3 protein] platycodin D results in decreased expression of TGFB1 protein
[platycodin D co-treated with osthol] results in decreased expression of TGFBR2 mRNA; [platycodin D co-treated with osthol] results in decreased expression of TGFBR2 protein
platycodin D inhibits the reaction [Ethanol results in increased expression of TLR4 mRNA]; platycodin D inhibits the reaction [Lipopolysaccharides affects the localization of TLR4 protein]
platycodin D inhibits the reaction [[[S100A8 protein binds to S100A9 protein] which results in increased localization of and results in increased activity of RELA protein] which results in increased expression of TNF protein]; platycodin D inhibits the reaction [Alloxan results in increased expression of and results in increased secretion of TNF protein]; platycodin D inhibits the reaction [Ethanol results in increased expression of and results in increased secretion of TNF protein] platycodin D inhibits the reaction [Ethanol results in increased expression of TNF protein]; platycodin D inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] platycodin D inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CCL17 mRNA]; platycodin D inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; platycodin D inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; platycodin D inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of STAT1 protein]
platycodin D inhibits the reaction [TNFSF11 protein results in increased expression of and results in increased activity of NFATC1 protein]; platycodin D inhibits the reaction [TNFSF11 protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; platycodin D inhibits the reaction [TNFSF11 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; platycodin D inhibits the reaction [TNFSF11 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] platycodin D inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein]
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased degradation of and results in increased phosphorylation of NFKBIA protein]
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased activity of NOS2 protein]; soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased secretion of NOS2 protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of NOS2 protein]
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of PTGS2 protein]
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]